title: Allogeneic BMT in a patient with CML and prior disseminated infection by mycobacterium avium complex.
abstract: A patient with chronic myeloid leukemia (CML) who developed a disseminated infection by mycobacterium avium complex (MAC) was successfully treated with rifampin, ethambutol, isoniazid, cycloserin and ciprofloxacin. Diagnosis was proven by histologic examination of hepatic biopsy and culture of the liver biopsy material. Two years later the patient underwent allogeneic bone marrow transplantation (BMT) from an HLA-matched sibling donor. Antimycobacterial prophylaxis to MAC with ethambutol, cycloserin and ciprofloxacin was given throughout the immediate post-transplant period. On day +25 post-BMT secondary prophylaxis was changed to ciprofloxacin and clarithromycin due to hepatic toxicity. Treatment was maintained until day 100 without side effects. There was no evidence of recurrent mycobacteriosis. Eight months after BMT the patient is well, with a good performance status and chronic graft-versus-host disease (GVHD) limited to the oral mucosa. Thus, MAC infection prior to transplant need not be a contraindication to successful BMT.
authors.affiliation: Department of Hematology, Marqués de Valdecilla University Hospital, University of Cantabria, Santander, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Hermida
authors.forename: C
authors.initials: C
authors.lastname: Richard
authors.forename: J
authors.initials: J
authors.lastname: Baro
authors.forename: J C
authors.initials: JC
authors.lastname: Garcia-Ruiz
authors.forename: G
authors.initials: G
authors.lastname: Barreiro
authors.forename: C
authors.initials: C
authors.lastname: Fariñas
authors.forename: A
authors.initials: A
authors.lastname: Zubizarreta
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy*; D015269:Mycobacterium avium Complex / Q000302:isolation & purification*; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications* / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents